Cargando…

Monitoring Cell Death in Regorafenib-Treated Experimental Colon Carcinomas Using Annexin-Based Optical Fluorescence Imaging Validated by Perfusion MRI

OBJECTIVE: To investigate annexin-based optical fluorescence imaging (OI) for monitoring regorafenib-induced early cell death in experimental colon carcinomas in rats, validated by perfusion MRI and multiparametric immunohistochemistry. MATERIALS AND METHODS: Subcutaneous human colon carcinomas (HT-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kazmierczak, Philipp M., Burian, Egon, Eschbach, Ralf, Hirner-Eppeneder, Heidrun, Moser, Matthias, Havla, Lukas, Eisenblätter, Michel, Reiser, Maximilian F., Nikolaou, Konstantin, Cyran, Clemens C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578959/ https://www.ncbi.nlm.nih.gov/pubmed/26393949 http://dx.doi.org/10.1371/journal.pone.0138452

Ejemplares similares

Correlation of Perfusion MRI and (18)F-FDG PET Imaging Biomarkers for Monitoring Regorafenib Therapy in Experimental Colon Carcinomas with Immunohistochemical Validation
por: Eschbach, Ralf S., et al.
Publicado: (2015)

Regorafenib Effects on Human Colon Carcinoma Xenografts Monitored by Dynamic Contrast-Enhanced Computed Tomography with Immunohistochemical Validation
por: Cyran, Clemens C., et al.
Publicado: (2013)

Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation
por: Eschbach, Ralf Stefan, et al.
Publicado: (2017)

(68)Ga-TRAP-(RGD)(3) Hybrid Imaging for the In Vivo Monitoring of α(v)ß(3)-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer
por: Kazmierczak, Philipp M., et al.
Publicado: (2016)

Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma
por: Kazmierczak, Philipp M., et al.
Publicado: (2018)

Monitoring Early Response to Anti-Angiogenic Therapy: Diffusion-Weighted Magnetic Resonance Imaging and Volume Measurements in Colon Carcinoma Xenografts
por: Schneider, Moritz Jörg, et al.
Publicado: (2014)

(18)F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma
por: Eschbach, Ralf S., et al.
Publicado: (2018)

Visualization, imaging and new preclinical diagnostics in radiation oncology
por: Cyran, Clemens C, et al.
Publicado: (2014)

Ex Vivo Perfusion-Simulation Measurements of Microbubbles as a Scattering Contrast Agent for Grating-Based X-Ray Dark-Field Imaging
por: Velroyen, Astrid, et al.
Publicado: (2015)

Circulating miR-21 as a prognostic biomarker in HCC treated by CT-guided high-dose rate brachytherapy
por: Stechele, Matthias, et al.
Publicado: (2023)

Age determination of vessel wall hematoma in spontaneous cervical artery dissection: A multi-sequence 3T Cardiovascular Magnetic resonance study
por: Habs, Maximilian, et al.
Publicado: (2011)

Reducing tumor growth and angiogenesis using a triple therapy measured with Contrast-enhanced ultrasound (CEUS)
por: Paprottka, Philipp Marius, et al.
Publicado: (2015)

Post-therapeutic microRNA-146a in liquid biopsies may determine prognosis in metastatic gastrointestinal cancer patients receiving (90)Y-radioembolization
por: Hirner-Eppeneder, Heidrun, et al.
Publicado: (2023)

Comparison of symptomatic and asymptomatic atherosclerotic carotid plaques using parallel imaging and 3 T black-blood in vivo CMR
por: Grimm, Jochen M, et al.
Publicado: (2013)

Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT
por: Kunz, Wolfgang G., et al.
Publicado: (2018)

Computed tomography angiography vs 3 T black-blood cardiovascular magnetic resonance for identification of symptomatic carotid plaques
por: Grimm, Jochen M, et al.
Publicado: (2014)

Characteristics of carotid atherosclerotic plaques of chronic lipid apheresis patients as assessed by In Vivo High-Resolution CMR - a comparative analysis
por: Grimm, Jochen M, et al.
Publicado: (2012)

High resolution carotid black-blood 3T MR with parallel imaging and dedicated 4-channel surface coils
por: Saam, Tobias, et al.
Publicado: (2009)

Non-Contrast-Enhanced MR Angiography at 3 Tesla in Patients with Advanced Peripheral Arterial Occlusive Disease
por: Thierfelder, Kolja M., et al.
Publicado: (2014)

The Big Picture: Evidence Base and Current Trials in Cardiac CT
por: Hetterich, Holger, et al.
Publicado: (2013)

State of affairs of hybrid imaging in Europe: two multi-national surveys from 2017
por: Gatidis, Sergios, et al.
Publicado: (2019)

In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media
por: Cyran, Clemens C., et al.
Publicado: (2013)

Expansive arterial remodeling of the carotid arteries and its effect on atherosclerotic plaque composition and vulnerability: an in-vivo black-blood 3T CMR study in symptomatic stroke patients
por: Saam, Tobias, et al.
Publicado: (2016)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

The annexins
por: Moss, Stephen E, et al.
Publicado: (2004)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

Differences in MR perfusion of malignant and benign cardiac tumors
por: Bauner, Kerstin U, et al.
Publicado: (2009)

Annexins in Glaucoma
por: Yap, Timothy E., et al.
Publicado: (2018)

A whole-body FDG-PET/CT Dataset with manually annotated Tumor Lesions
por: Gatidis, Sergios, et al.
Publicado: (2022)

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
por: Unseld, Matthias, et al.
Publicado: (2020)

Dual-Energy Computed Tomography of the Lung in COVID-19 Patients: Mismatch of Perfusion Defects and Pulmonary Opacities
por: Afat, Saif, et al.
Publicado: (2020)

Prevention and management of adverse events related to regorafenib
por: De Wit, Mieke, et al.
Publicado: (2013)

Correction: Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2019)

Targeting gastrointestinal stromal tumors: the role of regorafenib
por: Schroeder, Brett, et al.
Publicado: (2016)

Bioinformatics Analysis of Bacterial Annexins – Putative Ancestral Relatives of Eukaryotic Annexins
por: Kodavali, Praveen Kumar, et al.
Publicado: (2014)

Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib
por: Wang, Haochen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4cp8ag433iu5j8abbkndno78k6